• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Experience with tenofovir disoproxil fumarate for antiretroviral therapy.
【24h】

Experience with tenofovir disoproxil fumarate for antiretroviral therapy.

机译：经验丰富的替诺福韦富马酸替索罗非酯用于抗逆转录病毒疗法。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND RATIONALE/OBJECTIVE: Tenofovir disoproxil fumarate was approved in the US in 2001 and a few months later by the European Medicines Evaluation Agency for use in the EU, initially for treatment-experienced HIV patients with early virological failure. The following year the HIV indication was expanded to include antiretroviral treatment naive adults over 18 years of age. RESULTS AND CONCLUSIONS: Ongoing clinical trials of tenofovir disoproxil fumarate's safety and efficacy have confirmed its position as a long-term, safe, effective and convenient backbone component in combination antiretroviral therapy for HIV-infected patients. With its favourable resistance profile, it is also an option for treatment-experienced patients. This article describes the efficacy and safety of tenofovir disoproxil fumarate from ongoing and recent clinical trials, and key aspects of its broad, clinical experience since its introduction.
机译：背景和理由/目的：替诺福韦二富马酸富马酸替诺福韦于2001年在美国获得批准，几个月后，欧洲药品评估局批准在欧盟使用，最初用于具有治疗经验的早期病毒学失败的HIV患者。次年，HIV适应症扩大到包括18岁以上的初次接受抗逆转录病毒治疗的成年人。结果与结论：替诺福韦富马酸替诺福韦酯的安全性和有效性的正在进行的临床试验已证实其在艾滋病毒感染患者的联合抗逆转录病毒疗法中是长期，安全，有效和方便的骨干成分。凭借其良好的抗药性，它也是有治疗经验的患者的一种选择。本文从正在进行的和最新的临床试验中描述了替诺福韦富马酸替诺福韦的疗效和安全性，以及自引入以来广泛的临床经验的关键方面。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号